Will German Regulators Dampen Gilead Hopes For Its Stribild AIDS Drug?

German regulators have issued a preliminary decision that the Gilead Sciences once-daily, combination Stribild HIV treatment does not offer a benefit over the older Atripla medication. Gilead is appealing, but if regulators remain firm, the drugmaker may face 'referenced' pricing - Stribild would be lowered to the Atripla price and if other European Union countries adopt the same, the value if fixed-dose regimen products could be diminished.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news